Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WHILE THE PHASE 3 TRIAL OF VILOBELIMAB IN ULCERATIVE PYODERMA GANGRENOSUM (PG) WAS TERMINATED EARLIER THIS YEAR DUE TO FUTILITY REGARDING ITS PRESPECIFIED PRIMARY ENDPOINT (AS PREVIOUSLY DISCLOSED), SUBSEQUENT POST-HOC ANALYSES SUGGEST A POSITIVE TREND IN FAVOR OF VILOBELIMAB, WITH SIGNALS INDICATING A POTENTIALLY CONSISTENT TREATMENT EFFECT INFLARX ANTICIPATES MEETING WITH THE FDA TO DETERMINE A POTENTIAL DEVELOPMENT PATH FORWARD IN PG, WHICH THE COMPANY ANTICIPATES WOULD ONLY BE CONDUCTED IN COLLABORATION WITH A PARTNER JENA, GERMANY, DEC. 30, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY OUTLINED MULTIPLE DATA ANALYSES OF THE PHASE 3 STUDY FOR VILOBELIMAB IN PYODERMA GANGRENOSUM (PG), WHICH WAS TERMINATED EARLIER THIS YEAR AFTER AN INDEPENDENT DATA MONITORING COMMITTEE (IDMC) RECOMMENDED THE TRIAL BE STOPPED EARLY DUE TO FUTILITY.

INFLARX PROVIDES UPDATE ON PHASE 3 DATA ANALYSES FOR VILOBELIMAB IN PYODERMA GANGRENOSUM

JENA, GERMANY, DEC. 11, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED THAT THE WORLD HEALTH ORGANIZATION (WHO) HAS GRANTED THE INTERNATIONAL NONPROPRIETARY (GENERIC) NAME (INN) OF IZICOPAN TO THE COMPANY FOR ITS ORALLY AVAILABLE C5AR INHIBITOR, FORMERLY KNOWN AS INF904, IN ACCORDANCE WITH THE WHO'S PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR PHARMACEUTICAL SUBSTANCES. IN THE NEXT STEP OF THIS PROCESS, THE NAME IZICOPAN WILL BE PUBLISHED IN THE RECOMMENDED LIST OF INNS.

INFLARX ANNOUNCES INTERNATIONAL NONPROPRIETARY NAME OF IZICOPAN FOR INF904

PHASE 2A DATA SUPPORT ORAL C5AR INHIBITOR INF904 AS A POTENTIALLY TRANSFORMATIONAL AND BEST-IN-CLASS IMMUNOMODULATORY AGENT, INDICATING STRONG POTENTIAL FOR EFFICACY AND NO SAFETY SIGNALS OF CONCERN IN HS, OVER 4 WEEKS OF THERAPY, INFLARX OBSERVED RAPID AND CLINICALLY MEANINGFUL REDUCTIONS IN ABSCESSES AND NODULES (ANS) AND DRAINING TUNNELS (DTS), ROBUST HISCR RESPONSES THAT CONTINUED TO DEEPEN FOUR WEEKS AFTER THE TREATMENT PERIOD, WITH SUBSTANTIAL REDUCTIONS IN PATIENT REPORTED PAIN SCORES, OVERALL DEMONSTRATING THE POTENTIAL FOR BIOLOGIC-LIKE EFFICACY IN CSU, INFLARX OBSERVED SUBSTANTIAL REDUCTIONS IN THE 7-DAY URTICARIA ACTIVITY SCORE (UAS7) BROADLY ACROSS PATIENTS, AND PARTICULARLY IN THOSE WITH SEVERE DISEASE, AS WELL AS IMPROVED DISEASE CONTROL AS MEASURED BY THE URTICARIA CONTROL TEST (UCT7) WITH A PRIORITY OF ENABLING PHASE 2B DEVELOPMENT FOR INF904 IN HS, INFLARX CONTINUES ONGOING CLINICAL TRIAL PREPARATION TOWARDS ITS GOAL OF PHASE 2B INITIATION IN 2026 GIVEN INF904'S POTENTIAL AS A PIPELINE-IN-A-PRODUCT AND INCREASED INDUSTRY INTEREST IN THE C5AR MECHANISM OF ACTION, INFLARX CONTINUES TO FOSTER ACTIVE DIALOG WITH POTENTIAL COLLABORATORS IN AN EFFORT TO EXPEDITE THE COMPANY'S TOTAL DEVELOPMENT GOALS WITH INF904, AND TO ALSO DRIVE DEVELOPMENT IN CSU AND ADDITIONAL INFLAMMATORY DISORDERS INFLARX WILL HOST A WEBCAST TO DISCUSS THE TOPLINE DATA TODAY AT 8:00 AM EST / 2:00 PM CET JENA, GERMANY, NOV. 10, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED POSITIVE TOPLINE DATA FROM A PHASE 2A BASKET STUDY EXPLORING INF904 IN HS AND CSU.

INFLARX REPORTS POSITIVE PHASE 2A DATA FOR INF904 IN HIDRADENITIS SUPPURATIVE (HS) AND CHRONIC SPONTANEOUS URTICARIA (CSU)

COMPANY EXPECTS TO HOST A WEBCAST TO DISCUSS THE TOPLINE DATA ON MONDAY, NOVEMBER 10 AT 8:00 AM EST / 2:00 PM CET COMPANY ALSO EXPECTS TO PUBLISH THIRD QUARTER 2025 FINANCIAL RESULTS ON THE SAME DAY PRE-MARKET JENA, GERMANY, NOV. 07, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED THAT IT EXPECTS TO REPORT TOPLINE DATA FROM THE PHASE 2A CLINICAL TRIAL OF ORAL C5AR INHIBITOR INF904 IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (HS) AND CHRONIC SPONTANEOUS URTICARIA (CSU) IN A PRE-MARKET PRESS RELEASE ON MONDAY, NOVEMBER 10, 2025.

INFLARX TO ANNOUNCE TOPLINE DATA FROM PHASE 2A CLINICAL TRIAL OF INF904 IN HIDRADENITIS SUPPURATIVA AND CHRONIC SPONTANEOUS URTICARIA

JENA, GERMANY, OCT. 21, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED ITS PARTICIPATION IN THE GUGGENHEIM SECURITIES 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE. DETAILS ARE AS FOLLOWS:

INFLARX ANNOUNCES PARTICIPATION IN THE GUGGENHEIM SECURITIES 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE

JENA, GERMANY, SEPT. 12, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM (THE COMPANY), TODAY ANNOUNCED THAT IT HAS RECEIVED A WRITTEN NOTICE (THE NOTICE), DATED SEPTEMBER 11, 2025, FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ) INFORMING THE COMPANY THAT IT HAS REGAINED COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT SET FORTH UNDER NASDAQ LISTING RULE 5450(A)(1) (THE MINIMUM BID PRICE REQUIREMENT).

INFLARX REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

JENA, GERMANY, AUG. 21, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED IT WILL PARTICIPATE IN TWO INVESTOR CONFERENCES IN SEPTEMBER 2025. DETAILS ARE AS FOLLOWS:

INFLARX ANNOUNCES PARTICIPATION IN SEPTEMBERINVESTOR CONFERENCES

JENA, GERMANY, AUG. 07, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

INFLARX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

JENA, GERMANY, JULY 31, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT ITS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS ON AUGUST 7, 2025, BEFORE THE MARKET OPENS. NO CONFERENCE CALL IS PLANNED.

INFLARX TO REPORT SECOND QUARTER 2025 RESULTS ON AUGUST 7, 2025

JENA, GERMANY, JULY 11, 2025 (GLOBE NEWSWIRE) -- INFLARX N.V. (NASDAQ: IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS BY TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED THAT IT HAS RECEIVED A WRITTEN NOTICE (THE NOTICE), DATED JULY 11, 2025, FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ) INDICATING THAT, FOR THE LAST THIRTY (30) CONSECUTIVE BUSINESS DAYS, THE BID PRICE FOR THE COMPANY'S COMMON SHARES HAD CLOSED BELOW THE MINIMUM $1.00 PER SHARE REQUIREMENT FOR CONTINUED LISTING ON THE NASDAQ UNDER NASDAQ LISTING RULE 5450(A)(1) (THE MINIMUM BID PRICE RULE).

INFLARX ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE REQUIREMENT

JENA, GERMANY, MAY 28, 2025 (GLOBE NEWSWIRE) -- INFLARXN.V.(NASDAQ:IFRX), A BIOPHARMACEUTICAL COMPANY PIONEERING ANTI-INFLAMMATORY THERAPEUTICS TARGETING THE COMPLEMENT SYSTEM, TODAY ANNOUNCED THAT THE INDEPENDENT DATA MONITORING COMMITTEE (IDMC) CONDUCTING THE UNBLINDED INTERIM ANALYSIS FOR THE PHASE3 TRIAL FOR VILOBELIMAB IN PYODERMA GANGRENOSUM (PG), RECOMMENDED THAT THE TRIAL BE STOPPED DUE TO FUTILITY. THIS RECOMMENDATION WAS BASED ON DATA ANALYSIS OF THE FIRST 30 PATIENTS ENROLLED IN THE STUDY, WITH NO UNEXPECTED ADVERSE EVENTS NOTED BY THE IDMC. INFLARX AS THE STUDY SPONSOR REMAINS BLINDED TO THE STUDY RESULTS.

InflaRx N.V.

IFRX

Price

Financial Reports

No items found.

Press Releases

InflaRx N.V.

IFRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IFRX